Skip to main content

Table 1 Baseline characteristics of randomly assigned study participants

From: Effects of testosterone treatment on body fat and lean mass in obese men on a hypocaloric diet: a randomised controlled trial

  Testosterone group
(n = 49)
Placebo group
(n = 51)
P value
Age, years 54.3 (47.3–59.8) 52.8 (47.6–60.1) 0.93
Weight, kg 118.3 (15.7) 120.7 (19.6) 0.51
BMI, kg/m2 37.5 (34.9–40.5) 37.3 (34.7–41.6) 0.60
Waist circumference, cm 124 (118–131) 123 (117–136) 0.62
SBP, mmHg 135 (14) 130 (13) 0.06
DBP, mmHg 80 (78–88) 80 (78–85) 0.85
Handgrip, kg 44 (41–50) 46 (40–55) 0.65
Fat mass, kg 44.3 (10.0) 46.4 (10.6) 0.30
Fat mass, % 38.8 (33.5–42.3) 38.9 (36.0–43.5) 0.208
Lean mass, kg 68.1 (7.3) 67.4 (9.1) 0.67
ALM/height2, kg/m2 9.7 (1.0) 9.6 (0.8) 0.35
VAT area, mm2 25,088 (8617) 24,836 (9557) 0.89
Ischemic heart diseasea 6 (12.2 %) 6 (11.8 %) 0.94
Diabetes 10 (20.4 %) 12 (23.5 %) 0.71
Metformin 3 (6.1 %) 3 (5.9 %) 0.96
Statin use 14 (28.6 %) 15 (29.4 %) 1.0
Steps per day 6378 (4761–7543) 6371 (4816–7440) 0.79
Activity (%/day) 14.2 (5.7) 13.5 (4.5) 0.49
Physical performance test (sec) 36.2 (32.5–41.6) 37.1 (33.1–40.5) 0.40
TT, nmol/L, ECLIA 8.2 (2.5) 8.4 (2.3) 0.65
TT, nmol/L, LCMS/MS 6.8 (2.0) 7.0 (1.6) 0.55
cFT, pmol/L, ECLIA 195 (58) 208 (55) 0.23
cFT, pmol/L, LCMS/MS 159 (46) 172 (44) 0.15
SHBG, nmol/L 25 (18–31) 21 (17–26) 0.17
LH, IU/L 4.5 (3.3–5.6) 4.2 (3.1–5.2) 0.70
Fasting glucose, mmol/L 5.8 (5.3–6.1) 5.8 (5.4–6.4) 0.72
HOMA-IR 3.3 (1.0) 3.6 (1.1) 0.27
HbA1c, % 6.0 (5.6–6.2) 6.1 (5.8–6.5) 0.23
Total cholesterol, mmol/L 5.1 (4.3–5.6) 4.8 (4.4–5.7) 0.60
LDL-c, mmol/L 2.9 (0.9) 2.9 (1.0) 0.99
HDL-c, mmol/L 1.1 (1.0–1.3) 1.2 (1.0–1.3) 0.58
Triglycerides, mmol/L 1.9 (1.4–2.4) 1.7 (1.2–2.5) 0.38
Haematocrit 0.43 (0.02) 0.44 (0.02) 0.003
Haemoglobin, g/L 148 (8) 152 (9) 0.014
PSA, μg/L 0.7 (0.5–1.1) 0.7 (0.5–1.2) 0.79
  1. Data are mean (SD), median (IQR) based on normality testing, using the Kolmogorov–Smirnov test with Lilliefors correction, or number (%). P values were calculated for the difference between groups using t-test, Wilcoxon Signed Ranks Test, χ2 test, or Fisher exact test; P < 0.05 was considered significant
  2. aIschaemic heart disease denotes previous acute myocardial infarction, coronary artery bypass grafting, percutaneous transluminal coronary angioplasty
  3. BMI body mass index, DBP diastolic blood pressure, SBP systolic blood pressure, ALM appendicular lean mass, VAT visceral abdominal tissue, SHBG sex hormone binding globulin, TT testosterone, cFT calculated free testosterone, ECLIA electrochemiluminescence immunoassay, LCMS liquid chromatography-tandem mass spectroscopy, LH luteinising hormone, HbA1c glycated haemoglobin, LDL-c low density lipoprotein cholesterol, HDL-c high density lipoprotein cholesterol, PSA Prostate-specific antigen